Abstract
Traditional drug discovery screening assays tend to employ simplistic endpoint assays that often monitor the activity of a single target. While these approaches are amenable to high-throughput screening they provide limited information on how candidate drugs influence complex biological systems that exist in vivo. Such limitations are a contributing factor to high attrition rates of drugs as a consequence of poor efficacy in clinical trials.
Original language | English |
---|---|
Pages (from-to) | 44-50 |
Journal | European Pharmaceutical Review |
Volume | 13 |
Issue number | 5 |
Publication status | Published - 2008 |